Market Place
Sourcing Support
EU approves Gilead`s new injection for preventing HIV
27 Aug 2025 //
REUTERS
CVS Denies Coverage for Gilead`s Biannual PrEP Drug Yeztugo
21 Aug 2025 //
FIERCE PHARMA
Gilead Reports 7% Sales Decline for CAR-T`s Yescarta, Tecartus
12 Aug 2025 //
FIERCE PHARMA
AbbVie, Gilead, GSK Support Annual Hepatitis Elimination Drive
29 Jul 2025 //
FIERCE PHARMA
Lilly`s Kisunla, Gilead`s Pr Ep Drug Yeytuo Gain CHMP Nods
25 Jul 2025 //
FIERCE PHARMA
Gilead Gets CHMP Nod for Lenacapavir HIV Prevention
25 Jul 2025 //
BUSINESSWIRE
EU Backs Gilead`s Twice-Yearly Injection for HIV Prevention
25 Jul 2025 //
REUTERS
Gilead Sciences to Release Second Quarter 2025 Financial Results
24 Jul 2025 //
BUSINESSWIRE
Gilead`s Ongoing Commitment to End HIV Epidemic
23 Jul 2025 //
ACCESSWIRE
Hookipa, Having Sold Off Vaccines to Gilead, Opts to Wind Down
21 Jul 2025 //
FIERCE BIOTECH
WHO recommends Gilead`s twice-yearly injection for HIV prevention
15 Jul 2025 //
REUTERS
Gilead Unveils Lenacapavir Data for HIV Prevention at IAS 2025
14 Jul 2025 //
BUSINESSWIRE
Gilead Enlists Global Fund in Access Campaign for New PrEp Med
10 Jul 2025 //
PRESS RELEASE
Gilead, Global Fund Finalize Deal for Lenacapavir HIV Prevention
09 Jul 2025 //
BUSINESSWIRE
Scotus Ruling Paves Smooth Launch Path for Gilead`s Yeztugo
02 Jul 2025 //
FIERCE PHARMA
Gilead Blames Low Infection Rates for Ending 2 RSV Trials
28 Jun 2025 //
FIERCE BIOTECH
Gilead Shares Rise After Top Court Ruling on Preventive Coverage
28 Jun 2025 //
REUTERS
Gilead Signs up to $750 Million Cancer Drug Deal with Kymera
27 Jun 2025 //
PRESS RELEASE
Gilead Shares Kim’s Story of Growing Up With HIV in 1980s
24 Jun 2025 //
ACCESSWIRE
FDA approves Gilead`s twice-yearly injection for HIV prevention
19 Jun 2025 //
PRESS RELEASE
Gilead, Arcellx Continue to Safety of Multiple Myeloma Therapy
16 Jun 2025 //
ENDPTS
FDA Pause Gilead Trials Testing Experimental HIV pill Combo
11 Jun 2025 //
REUTERS
Kite Shows Yescarta Data for Outpatient Lymphoma Care at ASCO
01 Jun 2025 //
BUSINESSWIRE
Gilead bolsters Trodelvy with first-line breast cancer win
30 May 2025 //
FIERCE PHARMA
ASCENT-03 Trodelvy Shows Benefit in 1L mTNBC Patients
23 May 2025 //
BUSINESSWIRE
Gilead`s Trodelvy Chalks up Another Phase 3 Breast Cancer Win
23 May 2025 //
FIERCE PHARMA
Gilead pays partner Hookipa $10M for HBV, HIV vaccines
23 May 2025 //
FIERCE BIOTECH
Tomas Cihlar of Gilead Sciences on TIME`s 100
20 May 2025 //
ACCESSWIRE
Gilead Sciences Ireland signs MoU for public health in Abu Dhabi
16 May 2025 //
BIOSPECTRUM
Gilead and Kite to Present Data at 2025 ASCO and EHA
15 May 2025 //
BUSINESSWIRE
Gilead Sciences: Focusing on PBC Through Patient Stories
15 May 2025 //
ACCESSWIRE
Gilead tees up $11B in new US manufacturing, R&D investments
09 May 2025 //
FIERCE PHARMA
Earth Day Focus for Gilead Sciences - Every Action Has an Impact
08 May 2025 //
ACCESSWIRE
Gilead’s Livdelzi Shows Consistent Efficacy in PBC at EASL
07 May 2025 //
BUSINESSWIRE
Bulevirtide Study Shows Sustained Viral Suppression
07 May 2025 //
BUSINESSWIRE
The Centrifuge Sessions Focus on Fighting Devastating Diseases
06 May 2025 //
ACCESSWIRE
Gilead to pay $202 M in US settlement over HIV drug kickbacks
30 Apr 2025 //
REUTERS
Gilead to Present Latest Advancements in Liver Diseases
29 Apr 2025 //
BUSINESSWIRE
Gilead Sciences to Present at Upcoming Investor Conferences
29 Apr 2025 //
BUSINESSWIRE
Gilead supports long-acting PrEP launch despite uncertainties
25 Apr 2025 //
FIERCE PHARMA
Gilead posts profit, HIV prevention drug on track for mid-June
24 Apr 2025 //
REUTERS
Gilead Sciences Announces First Quarter 2025 Financial Results
24 Apr 2025 //
BUSINESSWIRE
Gilead mounts campaign to close UK’s ‘HIV gender gap’
23 Apr 2025 //
FIERCE PHARMA
Gilead Backs HIV Prevention Summit in Atlanta
22 Apr 2025 //
ACCESSWIRE
Gilead says Trodelvy-Keytruda combo effective for breast cancer
22 Apr 2025 //
REUTERS
Ipsen touts early launch results for liver disease drug Iqirvo
17 Apr 2025 //
FIERCE PHARMA
Nurix`s GS-6791/NX-0479 IRAK4 Degrader IND Cleared by FDA
17 Apr 2025 //
GLOBENEWSWIRE
Gilead Reprimanded Over Conference Wi-Fi Sponsorship
14 Apr 2025 //
FIERCE PHARMA
IDEAYA Biosciences Expands IDE397 and Trodelvy Combo in MTAP-Dele
10 Apr 2025 //
PR NEWSWIRE
Gilead Sciences to Release Q1 2025 Financial Results on April 24
10 Apr 2025 //
BUSINESSWIRE
Centrifuge Sessions Drive Cancer Research Innovation
03 Apr 2025 //
ACCESSWIRE
Gilead Sciences in Top Five on JUST List for Biopharma Companies
18 Mar 2025 //
ACCESSWIRE
Gilead Sciences - Women`s History Month Celebrated With Its Team
14 Mar 2025 //
ACCESSWIRE
Gilead Reveals New HIV Treatment and Cure Data at CROI 2025
12 Mar 2025 //
BUSINESSWIRE
Gilead sets aside $200M for settlement over HIV drug
05 Mar 2025 //
FIERCE PHARMA
MEDSIR, Debiopharm Dose First Patient In WIN-B Breast Cancer Trial
25 Feb 2025 //
BUSINESSWIRE
EMA Validates Gilead’s MAA For Lenacapavir In HIV Prevention
24 Feb 2025 //
BUSINESSWIRE
Gilead`s Seladelpar Gets EU Conditional Nod For Biliary Cholangitis
20 Feb 2025 //
BUSINESSWIRE
Gilead Showcases Autoimmune Impact In The Centrifuge Sessions
19 Feb 2025 //
ACCESSWIRE
Gilead Sciences to Present at Upcoming Investor Conferences
19 Feb 2025 //
BUSINESSWIRE
